Professor | Xiaoyan Pan | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xiaoyan Pan
Contact Information	panxy@wh.iov.cn
Language ability	Chinese, English
Province	Hubei

Upload Avatar (500 x 500)

Name

Xiaoyan Pan

Contact Information

panxy@wh.iov.cn

Language ability

Chinese, English

Province

Hubei

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Life Sciences
Academic Background & Achievements	2011-09--2016-06 PhD: Southern Medical University Achievement 1: Youth of the Year, 2020 Achievement 2: Outstanding Graduate, 2016
Work Experience	2020-09~Present - Wuhan Institute of Virology, Chinese Academy of Sciences - Associate Researcher 2018-08~2020-09 - Wuhan Institute of Virology, Chinese Academy of Sciences - Assistant Researcher 2016-08~2018-08 - Wuhan Institute of Virology, Chinese Academy of Sciences - Postdoctoral Researcher 2011-09~2016-06 - Southern Medical University - PhD
Awards	Youth of the Year (2020): Research Institute Outstanding Graduate (2016): Research Institute

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Life Sciences

Academic Background & Achievements

2011-09--2016-06 PhD: Southern Medical University
Achievement 1: Youth of the Year, 2020
Achievement 2: Outstanding Graduate, 2016

Work Experience

2020-09~Present - Wuhan Institute of Virology, Chinese Academy of Sciences - Associate Researcher
2018-08~2020-09 - Wuhan Institute of Virology, Chinese Academy of Sciences - Assistant Researcher
2016-08~2018-08 - Wuhan Institute of Virology, Chinese Academy of Sciences - Postdoctoral Researcher
2011-09~2016-06 - Southern Medical University - PhD

Awards

Youth of the Year (2020): Research Institute
Outstanding Graduate (2016): Research Institute

Areas of Focus	Vaccines Small Molecule Drugs Therapeutic Antibodies
Publications	Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB, 2nd Author, 2023 Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2, 2nd Author, 2023 Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants, 11th Author, 2023 Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation, 1st Author, 2022 Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein, 11th Author, 2022 CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity, 10th Author, 2022 High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors, 23rd Author, 2022 Why is the SARS-CoV-2 Omicron variant milder?, 3rd Author, 2022 PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element, 9th Author, 2022 Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein, Not mentioned, 2022 SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target, 4th Author, 2021 SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO, 3rd Author, 2021 A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates, 4th Author, 2021 Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses, 2nd Author, 2021 Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion, 2nd Author, 2021 Antiviral Bafilomycins from a Feces-Inhabiting Streptomyces sp., 3rd Author, 2021 Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Hypocrella bambusae Are SARS-CoV-2 Entry Inhibitors, 11th Author, 2021 High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors, 4th Author, 2021 The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids, 4th Author, 2020 Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein, 2nd Author, 2020 Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junin virus, 1st Author, 2020 Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro, 1st Author, 2020 Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein, 5th Author, 2019 Heat shock factor 1 suppresses the HIV-induced inflammatory response by inhibiting nuclear factor-κB, 1st Author, 2018 Novel neutralizing monoclonal antibodies against Junin virus, 1st Author, 2018 Pr-957, a selective immunoproteasome inhibitor, reactivates latent hiv-1 through p-tefb activation mediated by hsf-1, 5th Author, 2018 Resveratrol reactivates latent hiv through increasing histone acetylation and activating heat shock factor 1, 2nd Author, 2017 Heat Shock Factor 1 Mediates Latent HIV Reactivation, 1st Author, 2016 Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition, 1st Author

Areas of Focus

Vaccines
Small Molecule Drugs
Therapeutic Antibodies

Publications

Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB, 2nd Author, 2023
Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2, 2nd Author, 2023
Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants, 11th Author, 2023
Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation, 1st Author, 2022
Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein, 11th Author, 2022
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity, 10th Author, 2022
High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors, 23rd Author, 2022
Why is the SARS-CoV-2 Omicron variant milder?, 3rd Author, 2022
PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element, 9th Author, 2022
Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein, Not mentioned, 2022
SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target, 4th Author, 2021
SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO, 3rd Author, 2021
A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates, 4th Author, 2021
Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses, 2nd Author, 2021
Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion, 2nd Author, 2021
Antiviral Bafilomycins from a Feces-Inhabiting Streptomyces sp., 3rd Author, 2021
Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Hypocrella bambusae Are SARS-CoV-2 Entry Inhibitors, 11th Author, 2021
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors, 4th Author, 2021
The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids, 4th Author, 2020
Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein, 2nd Author, 2020
Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junin virus, 1st Author, 2020
Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro, 1st Author, 2020
Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein, 5th Author, 2019
Heat shock factor 1 suppresses the HIV-induced inflammatory response by inhibiting nuclear factor-κB, 1st Author, 2018
Novel neutralizing monoclonal antibodies against Junin virus, 1st Author, 2018
Pr-957, a selective immunoproteasome inhibitor, reactivates latent hiv-1 through p-tefb activation mediated by hsf-1, 5th Author, 2018
Resveratrol reactivates latent hiv through increasing histone acetylation and activating heat shock factor 1, 2nd Author, 2017
Heat Shock Factor 1 Mediates Latent HIV Reactivation, 1st Author, 2016
Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition, 1st Author

Immunization Infectious Diseases Viral Infections Drug Development Antiviral Agents Biopharmaceuticals Clinical Trials Molecular Biology Biotechnology Therapeutics

Hua Gu - Tongji University

Rongxiu Li - Shanghai Jiao Tong University

Jianming Zhu - Huazhong University of Science and Technology

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us